Share Price and Basic Stock Data
Last Updated: October 17, 2025, 9:27 pm
| PEG Ratio | 2.13 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Lincoln Pharmaceuticals Ltd operates in the competitive pharmaceuticals sector, with a current market capitalization of ₹1,051 Cr and a share price of ₹524. The company has demonstrated a consistent upward trend in revenue, reporting sales of ₹510 Cr for the fiscal year ending March 2023, which rose to ₹581 Cr for March 2024 and is set to reach ₹623 Cr for March 2025. This represents a healthy growth trajectory, particularly when considering the quarterly sales figures, which ranged from ₹112 Cr in March 2023 to ₹156 Cr in September 2023. The steady increase in sales is indicative of Lincoln’s ability to adapt to market demands and potentially expand its product offerings. However, fluctuations in quarterly performance, particularly a drop in sales to ₹112 Cr in March 2023, may require ongoing management focus to stabilize revenue streams. The company’s operational performance, supported by a reported operating profit margin (OPM) of 15% in the most recent quarter, highlights its operational efficiency amid rising costs.
Profitability and Efficiency Metrics
Lincoln Pharmaceuticals has reported robust profitability metrics, with a net profit of ₹82 Cr for the fiscal year ending March 2025, up from ₹73 Cr in March 2023. The earnings per share (EPS) have also shown a commendable increase, standing at ₹41.11 for March 2025, reflecting the company’s effective cost management strategies. The return on equity (ROE) is recorded at 12.8%, while return on capital employed (ROCE) stands at 17.3%, both indicating efficient use of capital and shareholder funds. The interest coverage ratio is exceptionally high at 91.70x, suggesting that the company operates without debt, which significantly reduces financial risk. However, the company’s cash conversion cycle (CCC) of 90 days and fluctuating operating profit margins (which peaked at 21% in September 2022 but have since stabilized around 15%) suggest areas for operational improvement. The ability to maintain profit margins in the face of cost pressures will be critical for future profitability.
Balance Sheet Strength and Financial Ratios
Lincoln Pharmaceuticals showcases a robust balance sheet with total borrowings reported at ₹0 Cr, reflecting a debt-free position that enhances its financial flexibility. The company’s reserves have grown to ₹652 Cr, indicating strong retained earnings which can be utilized for future growth initiatives. The current ratio stands at 4.84, significantly above the industry average, suggesting excellent liquidity and the ability to cover short-term liabilities comfortably. The price-to-book value (P/BV) ratio is reported at 1.98x, which is relatively high but may indicate investor confidence in the company’s future growth potential. Additionally, the company’s total assets have increased to ₹797 Cr as of March 2025, highlighting a solid asset base to support operations. However, the high valuation multiples could pose a risk if market sentiments shift or if the company fails to deliver on its growth expectations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lincoln Pharmaceuticals reveals a significant promoter holding of 49.78%, which indicates strong insider confidence in the company’s future. Foreign institutional investors (FIIs) have increased their stake to 5.13%, while domestic institutional investors (DIIs) remain minimal at just 0.01%. The public holds a substantial 45.08%, reflecting a diverse shareholder base. The number of shareholders has also risen to 31,784, suggesting growing interest from retail investors. This diversified ownership structure may enhance the company’s stability and resilience against market volatility. However, the low DII participation could be a concern, as institutional backing often lends credibility and stability to a stock. The gradual increase in FII stake suggests a positive shift in investor sentiment, which could be beneficial for the stock’s performance in the long run.
Outlook, Risks, and Final Insight
If Lincoln Pharmaceuticals can sustain its revenue growth and manage operating costs effectively, it may continue to enhance its profitability metrics. The lack of debt positions the company favorably against competitors, allowing for strategic investments in R&D or expansion without the burden of interest payments. However, risks remain, including potential fluctuations in raw material costs and competition within the pharmaceutical sector, which could pressure margins. Additionally, maintaining high operational efficiency while navigating the challenges of market dynamics will be crucial. Should the company successfully leverage its strong balance sheet to capitalize on growth opportunities, it may further solidify its position in the market. Conversely, any missteps in managing costs or failing to adapt to market trends could hinder its growth trajectory. Thus, a balanced approach to growth and risk management will be essential for Lincoln Pharmaceuticals moving forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lincoln Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 33.3 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,760 Cr. | 437 | 479/192 | 107 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,830.59 Cr | 1,186.24 | 50.51 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 141 | 134 | 112 | 136 | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 |
| Expenses | 107 | 112 | 107 | 96 | 115 | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 |
| Operating Profit | 17 | 29 | 27 | 17 | 21 | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 |
| OPM % | 14% | 21% | 20% | 15% | 15% | 20% | 20% | 13% | 15% | 18% | 16% | 16% | 15% |
| Other Income | 6 | 6 | 6 | 4 | 8 | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 21 | 32 | 31 | 17 | 25 | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 |
| Tax % | 28% | 26% | 29% | 26% | 25% | 25% | 26% | 16% | 20% | 24% | 28% | 29% | 22% |
| Net Profit | 15 | 24 | 22 | 13 | 19 | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 |
| EPS in Rs | 7.49 | 11.84 | 10.79 | 6.27 | 9.49 | 13.80 | 14.00 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 |
Last Updated: August 20, 2025, 7:40 am
Below is a detailed analysis of the quarterly data for Lincoln Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 168.00 Cr. (Mar 2025) to 154.00 Cr., marking a decrease of 14.00 Cr..
- For Expenses, as of Jun 2025, the value is 130.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 141.00 Cr. (Mar 2025) to 130.00 Cr., marking a decrease of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 15.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from -7.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 22.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 19.00 Cr..
- For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Mar 2025) to 22.00%, marking a decrease of 7.00%.
- For Net Profit, as of Jun 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 28.00 Cr., marking an increase of 16.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 13.82. The value appears strong and on an upward trend. It has increased from 5.78 (Mar 2025) to 13.82, marking an increase of 8.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 4:55 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 266 | 400 | 360 | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 |
| Expenses | 190 | 240 | 359 | 313 | 308 | 299 | 321 | 337 | 376 | 421 | 480 | 522 |
| Operating Profit | 20 | 26 | 41 | 47 | 53 | 68 | 66 | 87 | 96 | 90 | 100 | 101 |
| OPM % | 10% | 10% | 10% | 13% | 15% | 18% | 17% | 21% | 20% | 18% | 17% | 16% |
| Other Income | 2 | 7 | 7 | 2 | 5 | 5 | 11 | 5 | 10 | 22 | 34 | 22 |
| Interest | 7 | 8 | 10 | 7 | 5 | 4 | 2 | 2 | 1 | 2 | 1 | 2 |
| Depreciation | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 11 | 13 |
| Profit before tax | 12 | 20 | 33 | 37 | 46 | 62 | 67 | 84 | 96 | 100 | 122 | 109 |
| Tax % | 16% | 24% | 28% | 25% | 25% | 22% | 23% | 26% | 28% | 27% | 24% | 25% |
| Net Profit | 10 | 15 | 24 | 28 | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 |
| EPS in Rs | 6.53 | 9.20 | 14.52 | 14.06 | 17.31 | 24.36 | 25.72 | 31.12 | 34.63 | 36.40 | 46.58 | 41.11 |
| Dividend Payout % | 9% | 11% | 7% | 9% | 9% | 6% | 6% | 5% | 4% | 4% | 4% | 4% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | 60.00% | 16.67% | 25.00% | 40.00% | 4.08% | 21.57% | 11.29% | 5.80% | 27.40% | -11.83% |
| Change in YoY Net Profit Growth (%) | 0.00% | 10.00% | -43.33% | 8.33% | 15.00% | -35.92% | 17.49% | -10.28% | -5.49% | 21.60% | -39.23% |
Lincoln Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 10% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 18% |
| 3 Years: | 25% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 16% |
| 3 Years: | 15% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 9:50 am
Balance Sheet
Last Updated: July 25, 2025, 2:51 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 82 | 95 | 124 | 172 | 204 | 249 | 293 | 346 | 413 | 482 | 573 | 652 |
| Borrowings | 68 | 76 | 78 | 64 | 61 | 34 | 5 | 1 | 2 | 2 | 1 | 0 |
| Other Liabilities | 93 | 70 | 56 | 48 | 62 | 63 | 71 | 85 | 99 | 83 | 106 | 125 |
| Total Liabilities | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 |
| Fixed Assets | 65 | 66 | 98 | 103 | 117 | 121 | 123 | 111 | 132 | 151 | 179 | 182 |
| CWIP | 2 | 3 | 3 | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 |
| Investments | 0 | 0 | 0 | 10 | 11 | 18 | 34 | 81 | 97 | 91 | 139 | 174 |
| Other Assets | 192 | 190 | 174 | 186 | 219 | 225 | 232 | 259 | 290 | 339 | 379 | 437 |
| Total Assets | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 |
Below is a detailed analysis of the balance sheet data for Lincoln Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
- For Reserves, as of Mar 2025, the value is 652.00 Cr.. The value appears strong and on an upward trend. It has increased from 573.00 Cr. (Mar 2024) to 652.00 Cr., marking an increase of 79.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 125.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 106.00 Cr. (Mar 2024) to 125.00 Cr., marking an increase of 19.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 797.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 700.00 Cr. (Mar 2024) to 797.00 Cr., marking an increase of 97.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 182.00 Cr.. The value appears strong and on an upward trend. It has increased from 179.00 Cr. (Mar 2024) to 182.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 174.00 Cr.. The value appears strong and on an upward trend. It has increased from 139.00 Cr. (Mar 2024) to 174.00 Cr., marking an increase of 35.00 Cr..
- For Other Assets, as of Mar 2025, the value is 437.00 Cr.. The value appears strong and on an upward trend. It has increased from 379.00 Cr. (Mar 2024) to 437.00 Cr., marking an increase of 58.00 Cr..
- For Total Assets, as of Mar 2025, the value is 797.00 Cr.. The value appears strong and on an upward trend. It has increased from 700.00 Cr. (Mar 2024) to 797.00 Cr., marking an increase of 97.00 Cr..
Notably, the Reserves (652.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -48.00 | -50.00 | -37.00 | -17.00 | -8.00 | 34.00 | 61.00 | 86.00 | 94.00 | 88.00 | 99.00 | 101.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 154 | 163 | 73 | 92 | 111 | 122 | 96 | 98 | 90 | 98 | 102 | 97 |
| Inventory Days | 62 | 44 | 36 | 63 | 86 | 75 | 95 | 86 | 121 | 106 | 101 | 99 |
| Days Payable | 174 | 92 | 40 | 54 | 82 | 92 | 102 | 105 | 120 | 77 | 95 | 106 |
| Cash Conversion Cycle | 43 | 116 | 70 | 100 | 115 | 106 | 88 | 78 | 91 | 126 | 108 | 90 |
| Working Capital Days | 13 | 76 | 31 | 69 | 89 | 113 | 126 | 119 | 113 | 121 | 127 | 217 |
| ROCE % | 11% | 15% | 21% | 19% | 19% | 23% | 22% | 25% | 24% | 22% | 22% | 18% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 106 | 0.08 | 0.01 | 106 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| Diluted EPS (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| Cash EPS (Rs.) | 47.55 | 51.89 | 40.97 | 38.66 | 34.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 335.34 | 295.98 | 250.86 | 216.12 | 187.85 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 335.34 | 295.98 | 250.86 | 216.12 | 187.85 |
| Revenue From Operations / Share (Rs.) | 311.15 | 289.84 | 254.78 | 235.71 | 212.09 |
| PBDIT / Share (Rs.) | 61.89 | 67.07 | 55.76 | 52.66 | 46.42 |
| PBIT / Share (Rs.) | 55.45 | 61.76 | 51.18 | 48.62 | 42.64 |
| PBT / Share (Rs.) | 54.51 | 61.03 | 50.16 | 47.90 | 41.86 |
| Net Profit / Share (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.12 |
| NP After MI And SOA / Share (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| PBDIT Margin (%) | 19.89 | 23.13 | 21.88 | 22.34 | 21.88 |
| PBIT Margin (%) | 17.82 | 21.30 | 20.08 | 20.62 | 20.10 |
| PBT Margin (%) | 17.51 | 21.05 | 19.68 | 20.32 | 19.73 |
| Net Profit Margin (%) | 13.21 | 16.07 | 14.28 | 14.69 | 14.67 |
| NP After MI And SOA Margin (%) | 13.21 | 16.07 | 14.28 | 14.69 | 14.66 |
| Return on Networth / Equity (%) | 12.25 | 15.73 | 14.50 | 16.02 | 16.58 |
| Return on Capital Employeed (%) | 16.07 | 20.34 | 19.89 | 21.94 | 22.10 |
| Return On Assets (%) | 10.33 | 13.32 | 12.41 | 12.97 | 13.54 |
| Asset Turnover Ratio (%) | 0.83 | 0.90 | 0.90 | 0.95 | 0.99 |
| Current Ratio (X) | 4.71 | 4.84 | 5.08 | 3.90 | 4.17 |
| Quick Ratio (X) | 3.97 | 4.00 | 4.11 | 3.10 | 3.53 |
| Inventory Turnover Ratio (X) | 2.75 | 2.73 | 2.48 | 2.66 | 2.18 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 3.22 | 4.12 | 4.32 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 2.89 | 3.66 | 3.87 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 96.78 | 95.88 | 95.68 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 97.11 | 96.34 | 96.13 | 0.00 |
| Interest Coverage Ratio (X) | 65.84 | 91.70 | 55.01 | 72.68 | 59.44 |
| Interest Coverage Ratio (Post Tax) (X) | 44.74 | 64.69 | 36.91 | 48.79 | 40.86 |
| Enterprise Value (Cr.) | 1082.31 | 1159.77 | 646.08 | 574.49 | 436.11 |
| EV / Net Operating Revenue (X) | 1.74 | 2.00 | 1.27 | 1.22 | 1.03 |
| EV / EBITDA (X) | 8.73 | 8.63 | 5.79 | 5.45 | 4.70 |
| MarketCap / Net Operating Revenue (X) | 1.77 | 2.02 | 1.33 | 1.32 | 1.06 |
| Retention Ratios (%) | 0.00 | 96.77 | 95.87 | 95.67 | 0.00 |
| Price / BV (X) | 1.64 | 1.98 | 1.35 | 1.44 | 1.20 |
| Price / Net Operating Revenue (X) | 1.77 | 2.02 | 1.33 | 1.32 | 1.06 |
| EarningsYield | 0.07 | 0.07 | 0.10 | 0.11 | 0.13 |
After reviewing the key financial ratios for Lincoln Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For Diluted EPS (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For Cash EPS (Rs.), as of Mar 25, the value is 47.55. This value is within the healthy range. It has decreased from 51.89 (Mar 24) to 47.55, marking a decrease of 4.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 335.34. It has increased from 295.98 (Mar 24) to 335.34, marking an increase of 39.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 335.34. It has increased from 295.98 (Mar 24) to 335.34, marking an increase of 39.36.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 311.15. It has increased from 289.84 (Mar 24) to 311.15, marking an increase of 21.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.89. This value is within the healthy range. It has decreased from 67.07 (Mar 24) to 61.89, marking a decrease of 5.18.
- For PBIT / Share (Rs.), as of Mar 25, the value is 55.45. This value is within the healthy range. It has decreased from 61.76 (Mar 24) to 55.45, marking a decrease of 6.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 54.51. This value is within the healthy range. It has decreased from 61.03 (Mar 24) to 54.51, marking a decrease of 6.52.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For PBDIT Margin (%), as of Mar 25, the value is 19.89. This value is within the healthy range. It has decreased from 23.13 (Mar 24) to 19.89, marking a decrease of 3.24.
- For PBIT Margin (%), as of Mar 25, the value is 17.82. This value is within the healthy range. It has decreased from 21.30 (Mar 24) to 17.82, marking a decrease of 3.48.
- For PBT Margin (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has decreased from 21.05 (Mar 24) to 17.51, marking a decrease of 3.54.
- For Net Profit Margin (%), as of Mar 25, the value is 13.21. This value exceeds the healthy maximum of 10. It has decreased from 16.07 (Mar 24) to 13.21, marking a decrease of 2.86.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.21. This value is within the healthy range. It has decreased from 16.07 (Mar 24) to 13.21, marking a decrease of 2.86.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.25. This value is below the healthy minimum of 15. It has decreased from 15.73 (Mar 24) to 12.25, marking a decrease of 3.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 20.34 (Mar 24) to 16.07, marking a decrease of 4.27.
- For Return On Assets (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has decreased from 13.32 (Mar 24) to 10.33, marking a decrease of 2.99.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has decreased from 0.90 (Mar 24) to 0.83, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.71. This value exceeds the healthy maximum of 3. It has decreased from 4.84 (Mar 24) to 4.71, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 3.97. This value exceeds the healthy maximum of 2. It has decreased from 4.00 (Mar 24) to 3.97, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 4. It has increased from 2.73 (Mar 24) to 2.75, marking an increase of 0.02.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 3.22 (Mar 24) to 0.00, marking a decrease of 3.22.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 2.89 (Mar 24) to 0.00, marking a decrease of 2.89.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 96.78 (Mar 24) to 0.00, marking a decrease of 96.78.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 97.11 (Mar 24) to 0.00, marking a decrease of 97.11.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 65.84. This value is within the healthy range. It has decreased from 91.70 (Mar 24) to 65.84, marking a decrease of 25.86.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 44.74. This value is within the healthy range. It has decreased from 64.69 (Mar 24) to 44.74, marking a decrease of 19.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,082.31. It has decreased from 1,159.77 (Mar 24) to 1,082.31, marking a decrease of 77.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.74, marking a decrease of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 8.73. This value is within the healthy range. It has increased from 8.63 (Mar 24) to 8.73, marking an increase of 0.10.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.77, marking a decrease of 0.25.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 96.77 (Mar 24) to 0.00, marking a decrease of 96.77.
- For Price / BV (X), as of Mar 25, the value is 1.64. This value is within the healthy range. It has decreased from 1.98 (Mar 24) to 1.64, marking a decrease of 0.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.77, marking a decrease of 0.25.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lincoln Pharmaceuticals Ltd:
- Net Profit Margin: 13.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.07% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.25% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 44.74
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.97
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 12.2 (Industry average Stock P/E: 50.51)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Lincoln House, Ahmedabad Gujarat 380060 | investor@lincolnpharma.com http://www.lincolnpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kishor M Shah | Non Executive Chairman |
| Mr. Mahendra G Patel | Managing Director |
| Mr. Hashmukh I Patel | Whole Time Director |
| Mr. Munjal M Patel | Whole Time Director |
| Mr. Ashish R Patel | Whole Time Director |
| Mr. Rajnikant G Patel | Non Executive Director |
| Mr. Nareshkumar Suthar | Independent Director |
| Mr. Saurin J Parikh | Independent Director |
| Ms. Seema Mehta | Independent Director |
FAQ
What is the intrinsic value of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd's intrinsic value (as of 20 October 2025) is 419.93 which is 19.86% lower the current market price of 524.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,050 Cr. market cap, FY2025-2026 high/low of 980/499, reserves of ₹652 Cr, and liabilities of 797 Cr.
What is the Market Cap of Lincoln Pharmaceuticals Ltd?
The Market Cap of Lincoln Pharmaceuticals Ltd is 1,050 Cr..
What is the current Stock Price of Lincoln Pharmaceuticals Ltd as on 20 October 2025?
The current stock price of Lincoln Pharmaceuticals Ltd as on 20 October 2025 is 524.
What is the High / Low of Lincoln Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lincoln Pharmaceuticals Ltd stocks is 980/499.
What is the Stock P/E of Lincoln Pharmaceuticals Ltd?
The Stock P/E of Lincoln Pharmaceuticals Ltd is 12.2.
What is the Book Value of Lincoln Pharmaceuticals Ltd?
The Book Value of Lincoln Pharmaceuticals Ltd is 335.
What is the Dividend Yield of Lincoln Pharmaceuticals Ltd?
The Dividend Yield of Lincoln Pharmaceuticals Ltd is 0.34 %.
What is the ROCE of Lincoln Pharmaceuticals Ltd?
The ROCE of Lincoln Pharmaceuticals Ltd is 17.3 %.
What is the ROE of Lincoln Pharmaceuticals Ltd?
The ROE of Lincoln Pharmaceuticals Ltd is 12.8 %.
What is the Face Value of Lincoln Pharmaceuticals Ltd?
The Face Value of Lincoln Pharmaceuticals Ltd is 10.0.